Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study
المؤلفون المشاركون
Ren, Zheng-Gang
Yuan, Jia
Yin, Xin
Tang, Bei
Ma, Hui
Zhang, Lan
Li, Lixin
Chen, Rongxin
Xie, Xiaoying
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-07-28
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Objectives.
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains a challenge in management.
Transarterial chemoembolization (TACE) has been used for patients with PVTT but efficiency was limited with a median overall survival of 4 to 6.1 months.
The aim of this study is to evaluate the efficiency of TACE combined with sorafenib in HBV background HCC with PVTT.
Methods.
A total of 498 patients were enrolled in the study including 69 patients who received TACE combined with sorafenib and 429 patients treated with TACE alone between January 1st, 2008, and April 30st, 2014.
Using the 1:2 propensity score matching, 138 well-balanced patients were enrolled.
Overall survival (OS) was compared between the two groups.
The Kaplan-Meier method was used to evaluate the OS, and the differences between groups were analyzed with a log-rank test.
Results.
TACE combined with sorafenib improved the OS of the patients compared with TACE alone (13.0 vs 6.0 months, p<0.001).
After propensity score matching, the median OS of combination therapy and TACE were 13.0 and 7.0 months, respectively (p=0.001).
Subgroup analysis revealed that the patients younger than 60 years old, male patients, AFP more than 400ng/ml, tumor size more than 5cm, or type III/IV PVTT had OS benefits from TACE combined with sorafenib.
Conclusions.
Compared with TACE therapy alone, TACE combined with sorafenib could improve OS in HBV background HCC patients with PVTT.
The patients who are younger, male, or with more tumor burden may benefit more from combination therapy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yuan, Jia& Yin, Xin& Tang, Bei& Ma, Hui& Zhang, Lan& Li, Lixin…[et al.]. 2019. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1123713
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yuan, Jia…[et al.]. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1123713
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yuan, Jia& Yin, Xin& Tang, Bei& Ma, Hui& Zhang, Lan& Li, Lixin…[et al.]. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1123713
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1123713
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر